Real life use of natalizumab, fingolimod, dimethylfumarate, teriflunomide and alemtuzumab in Austria: benefit-risk data from the Austrian Multiple Sclerosis Treatment Registry

被引：0
|
作者：
Guger, M. [1 ]
Enzinger, C. [2 ]
Leutmezer, F. [3 ]
Kraus, J. [4 ]
Berger, T. [5 ]
机构：
[1] Kepler Univ Clin, Clin Neurol 2, Med Campus 3, Linz, Austria
[2] Med Univ Graz, Dept Neurol, Graz, Austria
[3] Med Univ Vienna, Dept Neurol, Vienna, Austria
[4] Publ Hosp Zell Am See, Dept Neurol, Zell Am See, Austria
[5] Med Univ Innsbruck, Dept Clin Neurol, Innsbruck, Austria
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1510
引用
收藏
页码：788 / 789
页数：2
相关论文
共 50 条
  • [31] Real-world data from the TACO (Teriflunomide in relapsing remitting multiple sclerosis patients assessing clinical benefit and patient-reported outcomes) study
    Gobbi, C.
    Achtnichts, L.
    Derfuss, T.
    Stellmes, P.
    Kamm, C. P.
    Agosti, R.
    Czaplinksi, A.
    Salmen, A.
    Zecca, C.
    Roesch, N.
    Kaiser, C.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 755 - 755
  • [32] Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity and Disability at Baseline: Real-Life Data From a Swiss Cohort
    Kallweit, Ulf
    Jelcic, Ilijas
    Braun, Nathalie
    Fischer, Heike
    Zoerner, Bjoern
    Schreiner, Bettina
    Sokolov, Arseny A.
    Martin, Roland
    Weller, Michael
    Linnebank, Michael
    CLINICAL NEUROPHARMACOLOGY, 2012, 35 (02) : 77 - 80
  • [33] Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort
    Kallweit, U.
    Jelcic, I.
    Braun, N.
    Fischer, H.
    Zoerner, B.
    Schreiner, B.
    Sokolov, A.
    Martin, R.
    Weller, M.
    Linnebank, M.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S429 - S429
  • [34] A COST-EFFECTIVENESS ANALYSIS USING REAL-WORLD DATA FROM THE MSBASE REGISTRY: COMPARING NATALIZUMAB TO FINGOLIMOD IN PATIENTS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Herring, W.
    Gould, I. G.
    Casamassima, G.
    Dort, T.
    Zhang, Y.
    Acosta, C.
    Hyde, R.
    Spelman, T.
    Butzkueven, H.
    VALUE IN HEALTH, 2018, 21 : S338 - S338
  • [35] The results of a 24-month controlled, prospective study of relapsing multiple sclerosis patients at risk for progressive multifocal encephalopathy, who switched from prolonged use of natalizumab to teriflunomide
    Cohan, Stanley
    Gervasi-Follmar, Tiffany
    Kamath, Aneesh
    Kamath, Vineetha
    Chen, Chiayi
    Smoot, Kyle
    Baraban, Elizabeth
    Edwards, Keith
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2021, 7 (04)
  • [36] A COST-EFFECTIVENESS ANALYSIS USING REAL-WORLD DATA FROM THE MSBASE REGISTRY: COMPARING NATALIZUMAB TO FINGOLIMOD IN PATIENTS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
    Herring, W.
    Gould, I. G.
    Ruiz, L.
    Dort, T.
    Zhang, Y.
    Acosta, C.
    Hyde, R.
    Spelman, T.
    Butzkueven, H.
    VALUE IN HEALTH, 2018, 21 : S338 - S338
  • [37] Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
    Ziemssen, Tjalf
    Thomas, Katja
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2017, 10 (10) : 343 - 359
  • [38] ROMMINA: (Real wOrld ndMM data IN Austria) analysis of frontline treatment patterns in transplant ineligible Multiple Myeloma patients with pre-defined profiles based on real world data of the Austrian Myeloma Registry (AMR)
    Weger, R.
    Willenbacher, E.
    Willenbacher, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 188 - 188
  • [39] RISK-BENEFIT ASSESSMENT OF THE USE OF RITUXIMAB FOR RHEUMATOID ARTHRITIS IN REAL LIFE: FINDINGS FROM 1984 PATIENTS FROM THE FRENCH AUTOIMMUNITY AND RITUXIMAB REGISTRY
    Nguyen, Y.
    Mariette, X.
    Gottenberg, J. E.
    Iudici, M.
    Morel, J.
    Vittecoq, O.
    Constantin, A.
    Flipo, R. M.
    Schaeverbeke, T.
    Sibilia, J.
    Ravaud, P.
    Porcher, R.
    Seror, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 316 - 316
  • [40] The effect of alemtuzumab treatment in relapsing remitting multiple sclerosis: real-world data from a four-year prospective one center study
    Sandgren, S.
    Novakova, L.
    Axelsson, M.
    Malmestrom, C.
    Lycke, J.
    Zetterberg, H.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 555 - 556
12345